← Eichor
Condition: Brca1 Gene Mutation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Brca1 Gene Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations
Phase N/A · 1 location(s) · Institute of Cancer Research, United Kingdom · NCT02705846A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ov
Phase N/A · 1 location(s) · Peking University Third Hospital · NCT07532434Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
Phase 2 · 3 location(s) · Okayama University · NCT05485766BRCA Mutation Carriers' Platform a Multicenter Study
Phase N/A · 40 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT07253051Prediction of Germline BRCA 1/2 Genes From Healthy Ovaries
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT05769517Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene
NA · 1 location(s) · CHU de Quebec-Universite Laval · NCT06817694Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT03702309Study of How People Make Decisions About Prostate Cancer Risk
Phase N/A · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT07197723An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Inte
NA · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT05420064Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
Phase 1 · 1 location(s) · Varun Monga, MBBS · NCT06177171TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
NA · 66 location(s) · University Medical Center Nijmegen · NCT04294927MEASUREMENT OF CIRCULATING MUTATION BURDEN
Phase N/A · 1 location(s) · Centre Francois Baclesse · NCT06792721Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomark
NA · 25 location(s) · Institut Claudius Regaud · NCT05378204SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Phase 1 · 2 location(s) · General Oncology, Inc. · NCT04150042Pancreas Registry and High Risk Registry
Phase N/A · 2 location(s) · Icahn School of Medicine at Mount Sinai · NCT02775461Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and M
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT04431024PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
Phase 3 · 1 location(s) · Guangdong Provincial People's Hospital · NCT06533384Combination Therapy in Cancers With Mutations in DNA Repair Genes
Phase 1 · 1 location(s) · University of California, San Francisco · NCT05694715A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Phase 1/Phase 2 · 14 location(s) · 858 Therapeutics, Inc. · NCT06395519Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes
Phase N/A · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT03396341Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Phase 1 · 8 location(s) · Senhwa Biosciences, Inc. · NCT04890613Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04090567A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)
NA · 1 location(s) · Vasileios Kalles · NCT07292246Registry of Subjects at Risk of Pancreatic Cancer
Phase N/A · 4 location(s) · Associazione Italiana per lo Studio del Pancreas · NCT04095195Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 14 location(s) · Acerand Therapeutics (Shanghai) Limited · NCT06380660Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+
Phase 2 · 36 location(s) · GBG Forschungs GmbH · NCT06201234Prophylactic Irradiation to the Contralateral Breast for BCAs Patients
NA · 8 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT04960839The Cancer of the Pancreas Screening-5 CAPS5)Study
Phase 3 · 9 location(s) · Johns Hopkins University · NCT02000089COsegregation of VARiants in Panel of Genes
NA · 62 location(s) · Institut Curie · NCT01689584Prostate Cancer Genetic Risk Evaluation and Screening Study
Phase N/A · 1 location(s) · Massachusetts General Hospital · NCT05129605
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.